Combined Treatment of Bladder Cancer Cell Lines with Lapatinib and Varying Chemotherapy Regimens—Evidence of Schedule-Dependent Synergy
Author:
Publisher
Elsevier BV
Subject
Urology
Reference27 articles.
1. Global cancer statistics 2002;Parkin;CA Cancer J Clin,2005
2. A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Loehrer;J Clin Oncol,1992
3. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium;Sternberg;J Urol,1985
4. A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours;Logothetis;J Clin Oncol,1990
5. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomised, multinational, multicentre, phase III study;von der Maase;J Clin Oncol,2000
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Longitudinal drug synergy assessment using convolutional neural network image-decoding of glioblastoma single-spheroid cultures;Neuro-Oncology Advances;2023-01-01
2. Bladder cancer organoids as a functional system to model different disease stages and therapy response;2022-04-01
3. Proteomics Analysis of Tangeretin-Induced Apoptosis through Mitochondrial Dysfunction in Bladder Cancer Cells;International Journal of Molecular Sciences;2019-02-26
4. Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway;Oncology Reports;2019-02-11
5. Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review;Urologia Internationalis;2018-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3